Oncaspar

RSS

pegaspargase

Authorised
This medicine is authorised for use in the European Union.

Overview

Oncaspar is a cancer medicine used in adults and children to treat acute lymphoblastic leukaemia (ALL), a cancer of white blood cells called lymphoblasts. Oncaspar is used in combination with other cancer medicines.

It contains the active substance pegaspargase.

This EPAR was last updated on 16/05/2019

Authorisation details

Product details
Name
Oncaspar
Agency product number
EMEA/H/C/003789
Active substance
pegaspargase
International non-proprietary name (INN) or common name
pegaspargase
Therapeutic area (MeSH)
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anatomical therapeutic chemical (ATC) code
L01XX24
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Les Laboratoires Servier
Revision
8
Date of issue of marketing authorisation valid throughout the European Union
14/01/2016
Contact address
Les laboratoires Servier
50, rue Carnot
F-92284 Suresnes Cedex
France

Product information

26/04/2019 Oncaspar - EMEA/H/C/003789 - PSUSA/00010457/201807

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.

Assessment history

How useful was this page?

Add your rating
Average
1 rating